

Enzyme Kinetics And Inhibition

Garrett/Grisham, Biochemistry with a Human Focus


Table 11.1

Table 11.1 A Comparison of Enzyme-Catalyzed Reactions and Their Uncatalyzed Counterparts


Reaction	Enzyme	Uncatalyzed Rate, v_u (sec^{-1})	Catalyzed Rate, v_e (sec^{-1})	v_e/v_u
$\text{CH}_3\text{—O—PO}_3^{2-} + \text{H}_2\text{O} \longrightarrow \text{CH}_3\text{OH} + \text{HPO}_4^{2-}$	Alkaline phosphatase	1×10^{-15}	14	1.4×10^{16}
$\text{H}_2\text{N—}\overset{\text{O}}{\parallel}\text{C—NH}_2 + 2 \text{H}_2\text{O} + \text{H}^+ \longrightarrow 2 \text{NH}_4^+ + \text{HCO}_3^-$	Urease	3×10^{-10}	3×10^4	1×10^{14}
$\text{R—}\overset{\text{O}}{\parallel}\text{C—O—CH}_2\text{CH}_3 + \text{H}_2\text{O} \longrightarrow \text{RCOOH} + \text{HOCH}_2\text{CH}_3$	Chymotrypsin	1×10^{-10}	1×10^2	1×10^{12}
$\text{Glycogen} + \text{P}_i \longrightarrow \text{Glycogen} + \text{Glucose-1-P}$ (n) ($n - 1$)	Glycogen phosphorylase	$< 5 \times 10^{-15}$	1.6×10^{-3}	$> 3.2 \times 10^{11}$
$\text{Glucose} + \text{ATP} \longrightarrow \text{Glucose-6-P} + \text{ADP}$	Hexokinase	$< 1 \times 10^{-13}$	1.3×10^{-3}	$> 1.3 \times 10^{10}$
$\text{CH}_3\text{CH}_2\text{OH} + \text{NAD}^+ \longrightarrow \text{CH}_3\overset{\text{O}}{\parallel}\text{CH} + \text{NADH} + \text{H}^+$	Alcohol dehydrogenase	$< 6 \times 10^{-12}$	2.7×10^{-5}	$> 4.5 \times 10^6$
$\text{CO}_2 + \text{H}_2\text{O} \longrightarrow \text{HCO}_3^- + \text{H}^+$	Carbonic anhydrase	10^{-2}	10^5	1×10^7
$\text{Creatine} + \text{ATP} \longrightarrow \text{Cr-P} + \text{ADP}$	Creatine kinase	$< 3 \times 10^{-9}$	4×10^{-5}	$> 1.33 \times 10^4$

Adapted from Koshland, D., 1956. *Journal of Cellular Comparative Physiology*, Supp. 1 **47**:217.

Substrate Specificity




Stereospecificity




**Only one enantiomer
will fit correctly into
active site**

Allosteric and Feedback Regulation of ACTase




**I
N
H
I
B
I
T
I
O
N**


6 enzymatic
reaction steps



Cytidine triphosphate (CTP)




Garrett/Grisham, Biochemistry with a Human Focus
Figure 10.8




Lineweaver-Burke Plot

Garrett/Grisham, Biochemistry with a Human Focus
Figure 10.9

$$\frac{1}{v} = \frac{K_m}{V_{\max}} \left(\frac{1}{[S]} \right) + \frac{1}{V_{\max}}$$




Competitive Inhibition




Because the inhibitor competes with substrate, K_M is changed.

(a)



(b)




(c)


V_{max} stays the same because $ES \rightarrow EP$ is same rate once S is bound.

Competitive Inhibition



Garrett/Grisham, Biochemistry with a Human Focus
Figure 10.12



Non-Competitive Inhibition



Because the inhibitor changes the rate of catalysis by inducing a conformational change in E, V_{max} is changed.




K_M stays the same because S binding is not affected by I binding.

Non-competitive Inhibition

Garrett/Grisham, Biochemistry with a Human Focus

Figure 10.14




Mixed Inhibition

Garrett/Grisham, Biochemistry with a Human Focus


Figure 10.15

(a) $K_I < K_I'$



Inhibitor binds remotely from the active site but changes both catalysis rate (V_{max}) and substrate binding (K_m)



(b) $K_I' < K_I$



Phosphodiesterase Inhibitor

If can get smooth muscle of blood vessel walls to relax, then treat angina and high blood pressure

Smooth muscle cells relax:



Phosphodiesterases (PDE) cleave cGMP to GMP causing muscle contraction

**Inhibit PDE 5 (isozyme prevalent in vascular tissue)
At least 9 isozymes.**

**Competitive inhibitor of PDE developed and marketed
Didn't work well**

